Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRGNASDAQ:LEXXNASDAQ:PMNNASDAQ:THAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRGBullfrog AI$1.65-4.6%$1.75$1.23▼$4.84$16.29M0.61396,653 shs283,152 shsLEXXLexaria Bioscience$0.96-4.0%$1.12$0.92▼$4.38$17.56M0.84148,589 shs97,514 shsPMNPromis Neurosciences$0.49-1.2%$0.54$0.47▼$2.37$16.34M-0.0879,305 shs6,697 shsTHARTharimmune$1.34-6.3%$1.40$0.95▼$6.39$3.80M1.04371,434 shs29,721 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRGBullfrog AI-4.62%-2.37%-10.33%-6.25%-16.67%LEXXLexaria Bioscience-4.00%-1.69%0.00%-45.76%-67.68%PMNPromis Neurosciences-1.20%-4.91%-3.70%-23.41%-68.40%THARTharimmune-6.29%+3.88%-0.74%-6.94%-54.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRGBullfrog AI0.8466 of 5 stars0.05.00.00.00.62.50.0LEXXLexaria Bioscience1.9958 of 5 stars3.52.00.00.01.11.70.6PMNPromis Neurosciences1.7872 of 5 stars3.52.00.00.00.00.81.3THARTharimmune2.1659 of 5 stars3.85.00.00.00.00.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRGBullfrog AI 0.00N/AN/AN/ALEXXLexaria Bioscience 3.00Buy$7.00629.17% UpsidePMNPromis Neurosciences 3.00Buy$4.50810.93% UpsideTHARTharimmune 3.50Strong Buy$17.001,168.66% UpsideCurrent Analyst Ratings BreakdownLatest THAR, LEXX, BFRG, and PMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025PMNPromis NeurosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/1/2025PMNPromis NeurosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRGBullfrog AI$60K259.05N/AN/A$0.57 per share2.89LEXXLexaria Bioscience$460K36.65N/AN/A$0.48 per share2.00PMNPromis NeurosciencesN/AN/AN/AN/A$0.50 per shareN/ATHARTharimmuneN/AN/AN/AN/A$0.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRGBullfrog AI-$6.99M-$0.81N/A∞N/AN/A-163.23%-139.94%N/ALEXXLexaria Bioscience-$5.80M-$0.59N/AN/AN/A-1,784.03%-111.84%-100.48%7/11/2025 (Estimated)PMNPromis Neurosciences$2.78M-$0.05N/AN/AN/AN/A-186.19%-98.56%8/6/2025 (Estimated)THARTharimmune-$12.20M-$7.88N/A∞N/AN/A-489.33%-264.34%N/ALatest THAR, LEXX, BFRG, and PMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/11/2025N/ALEXXLexaria Bioscience-$0.15N/AN/AN/A$0.17 millionN/A5/13/2025Q1 2025BFRGBullfrog AIN/A-$0.21N/A-$0.21N/AN/A5/12/2025Q1 2025PMNPromis Neurosciences-$0.14-$0.21-$0.07-$0.21N/AN/A5/12/2025Q1 2025THARTharimmune-$0.84-$0.99-$0.15-$0.99N/AN/A4/14/2025Q2 2025LEXXLexaria Bioscience-$0.16-$0.15+$0.01-$0.15$0.14 million$0.17 million3/31/2025Q4 2024PMNPromis Neurosciences-$0.14-$0.02+$0.12-$0.02N/AN/A3/25/2025Q4 2024THARTharimmuneN/A-$2.02N/A-$2.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRGBullfrog AIN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRGBullfrog AIN/A4.874.87LEXXLexaria BioscienceN/A4.244.24PMNPromis NeurosciencesN/A3.363.36THARTharimmuneN/A0.670.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRGBullfrog AI0.96%LEXXLexaria Bioscience13.06%PMNPromis Neurosciences50.13%THARTharimmune1.16%Insider OwnershipCompanyInsider OwnershipBFRGBullfrog AI33.90%LEXXLexaria Bioscience26.40%PMNPromis Neurosciences6.11%THARTharimmune10.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRGBullfrog AI49.42 million6.22 millionNot OptionableLEXXLexaria Bioscience717.56 million12.92 millionNot OptionablePMNPromis Neurosciences532.69 million30.69 millionNot OptionableTHARTharimmune22.66 million2.40 millionNot OptionableTHAR, LEXX, BFRG, and PMN HeadlinesRecent News About These CompaniesTharimmune CFO Don Kim ResignsJune 17, 2025 | marketwatch.comTharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of DirectorsJune 17, 2025 | accessnewswire.comTharimmune announces executive changes and new agreementsJune 13, 2025 | investing.comTharimmune advances opioid prophylaxis drug TH104May 7, 2025 | investing.comTharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA FeedbackMay 6, 2025 | accessnewswire.comTharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL ConferencesMay 1, 2025 | accessnewswire.comTharimmune Appoints Clay Kahler and Gary Stetz to its Board of DirectorsApril 30, 2025 | accessnewswire.comTharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA FeedbackApril 28, 2025 | sacbee.comTharimmune announces board retirements ahead of annual meetingApril 26, 2025 | investing.comTharimmune Inc.: Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of DirectorsApril 15, 2025 | finanznachrichten.deTharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of DirectorsApril 15, 2025 | accessnewswire.comTharimmune reports data on new biparatopic biologicsApril 9, 2025 | bioworld.comTharimmune announces preclinical data from expanded pipeline with HS1940April 9, 2025 | markets.businessinsider.comTharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) TechnologyApril 7, 2025 | accessnewswire.comTharimmune receives Nasdaq non-compliance noticeApril 6, 2025 | investing.comTharimmune announces FDA feedback on NDA path for TH104April 1, 2025 | markets.businessinsider.comTharimmune announces FDA feedback on TH104 NDA pathApril 1, 2025 | markets.businessinsider.comTharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid ExposureMarch 31, 2025 | accessnewswire.comTharimmune announce preclinical TH023 resultsMarch 25, 2025 | markets.businessinsider.comTharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alphaMarch 24, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTHAR, LEXX, BFRG, and PMN Company DescriptionsBullfrog AI NASDAQ:BFRG$1.65 -0.08 (-4.62%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.67 +0.02 (+1.21%) As of 06/20/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Lexaria Bioscience NASDAQ:LEXX$0.96 -0.04 (-4.00%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.00 +0.04 (+4.17%) As of 06/20/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Promis Neurosciences NASDAQ:PMN$0.49 -0.01 (-1.20%) Closing price 06/20/2025 03:55 PM EasternExtended Trading$0.50 +0.01 (+1.82%) As of 06/20/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Tharimmune NASDAQ:THAR$1.34 -0.09 (-6.29%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.34 +0.00 (+0.37%) As of 06/20/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
